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Neuroanatomical spread of amyloid b and tau
in Alzheimer’s disease: implications for
primary prevention
Philip S. Insel,1,2 Elizabeth C. Mormino,3 Paul S. Aisen,4 Wesley K. Thompson5 and
Michael C. Donohue4
With recent advances in our understanding of the continuous pathophysiological changes that begin many years prior to symptom
onset, it is now apparent that Alzheimer’s disease cannot be adequately described by discrete clinical stages, but should also incorp-
orate the continuum of biological changes that precede and underlie the clinical representation of the disease. By jointly considering
longitudinal changes of all available biomarkers and clinical assessments, variation within individuals can be integrated into a sin-
gle continuous measure of disease progression and used to identify the earliest pathophysiological changes. Disease time, a measure
of disease severity, was estimated using a Bayesian latent time joint mixed-effects model applied to an array of imaging, biomarker
and neuropsychological data. Trajectories of regional amyloid b and tau PET uptake were estimated as a function of disease time.
Regions with early signs of elevated amyloid b uptake were used to form an early, focal composite and compared to a commonly
used global composite, in a separate validation sample. Disease time was estimated in 279 participants (183 cognitively unimpaired
individuals, 61 mild cognitive impairment and 35 Alzheimer’s disease dementia patients) with available amyloid b and tau PET
data. Amyloid b PET uptake levels in the posterior cingulate and precuneus start high and immediately increase with small
increases of disease time. Early elevation in tau PET uptake was found in the inferior temporal lobe, amygdala, banks of the super-
ior temporal sulcus, entorhinal cortex, middle temporal lobe, inferior parietal lobe and the fusiform gyrus. In a separate validation
sample of 188 cognitively unimpaired individuals, the early, focal amyloid b PET composite showed a 120% increase in the accu-
mulation rate of amyloid b compared to the global composite (P<0.001), resulting in a 60% increase in the power to detect a
treatment effect in a primary prevention trial design. Ordering participants on a continuous disease time scale facilitates the inspec-
tion of the earliest signs of amyloid b and tau pathology. To detect early changes in amyloid b pathology, focusing on the earliest
sites of amyloid b accumulation results in more powerful and efficient study designs in early Alzheimer’s disease. Targeted compo-
sites could be used to re-examine the thresholds for amyloid b-related study inclusion, especially as the field shifts to focus on
primary and secondary prevention. Clinical trials of anti-amyloid b treatments may benefit from the use of focal composites when
estimating drug effects on amyloid b and tau changes in populations with minimal amyloid b and tau pathology and limited
expected short-term accumulation.
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Abbreviations: Ab ¼ amyloid b; AD ¼ Alzheimer’s disease; ADAS-cog ¼ Alzheimer’s disease assessment scale, cognitive subscale;
ADNI ¼ Alzheimer’s Disease Neuroimaging Initiative; AIC ¼ Akaike information criterion; APOE ¼ Apolipoprotein E; BSTS ¼
banks of the superior temporal sulcus; CDR ¼ clinical dementia rating; CI ¼ confidence interval; CU ¼ cognitively unimpaired;
EMCI ¼ early mild cognitive impairment; LMCI ¼ late mild cognitive impairment; LTJMM ¼ latent time joint mixed-effects
model; LTL ¼ lateral temporal lobe; MCI ¼ mild cognitive impairment; MMSE ¼ mini-mental state exam; MTL ¼ medial temporal
lobe; pCU ¼ cognitively unimpaired to mild cognitive impairment progressors; pMCI ¼ mild cognitive impairment to Alzheimer’s
disease progressors; ROI ¼ region of interest
Introduction
Traditionally, Alzheimer’s disease (AD) has been primar-
ily described in terms of discrete clinical stages. However,
with recent advances in our understanding of the con-
tinuous pathophysiological changes that begin many years
prior to symptom onset, it is now apparent that AD can-
not be adequately described by clinical stages, but should
also incorporate the continuum of biological changes that
precede and underlie the clinical representation of the dis-
ease (Aisen et al., 2017). Conceptualizing the progression
of AD as a continuum of overlapping pathological and
subsequent clinical changes will facilitate a realistic exam-
ination of the time course of the disease. Clarifying this
time course, from initial biomarker changes to severe
functional impairment, is essential for accurate early diag-
nosis, clinical trial enrollment, disease monitoring and
eventual disease prevention and management.
The likelihood of successfully treating AD may be
highest in the earliest stages of the disease, requiring a
detailed understanding of incipient biomarker changes.
Considerable evidence confirms the accumulation of fi-
brillar amyloid b (Ab) and aggregates of hyperphos-
phorylated tau, the pathognomonic lesions, as early AD
biomarker changes. In this study, we focus on the early
development of Ab and tau pathology in order to pro-
vide finer detail about the temporal course of early
neuropathological changes in AD. By jointly considering
longitudinal changes of an array of neuropsychological,
imaging and biomarker data, the variation within indi-
viduals and the associations among multiple outcomes
are simultaneously integrated into a single continuous
measure of disease progression (Donohue et al., 2014;
Li et al., 2017, 2018). Using estimates of each partici-
pant’s location on the disease continuum, or ‘disease
time’, we sought to estimate a temporal ordering of spa-
tial changes of Ab and tau lesions throughout the brain.
After identifying the earliest regions to demonstrate
pathological changes, we tested the performance of these
early regions in hypothetical primary and secondary pre-
vention clinical trial settings in a separate validation
sample.
Graphical Abstract
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Materials and methods
Participants
Data were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.us-
c.edu, www.adni-info.org). This study was approved by
the Institutional Review Boards of all of the participating
institutions. Informed written consent was obtained from
all participants at each site. The population in this study
included ADNI participants with measurements of both
Ab and tau PET. All available participants who were
cognitively unimpaired (CU), Abþ mild cognitive impair-
ment (MCI) or Abþ AD dementia at baseline were
included, where Abþ was defined using a previously
established threshold (SUVR ¼ 1.10) (Joshi et al., 2012).
Impaired Ab participants were excluded due to impair-
ment ostensibly unrelated to AD.
A separate validation sample included CU ADNI partic-
ipants with measurements of Ab who were not included
in the first part of the analysis because of missing tau
PET information.
PET imaging and CSF Ab
Methods to acquire and process Ab (18F-florbetapir) PET
image data were described previously (Landau et al.,
2012). Twenty Ab PET region of interests (ROIs) were
analysed: the inferior, middle and superior temporal lobe;
the precuneus, supramarginal gyrus, inferior and superior
parietal lobe; the isthmus, posterior, caudal and rostral
anterior cingulate; and the pars opercularis, pars triangu-
laris, pars orbitalis, caudal and rostral middle frontal,
medial and lateral orbitofrontal, frontal pole and superior
frontal lobe.
Methods to acquire and process tau (18F-flortaucipir)
PET image data were described previously (Maass et al.,
2017). Thirty tau ROIs were analysed: the amygdala,
entorhinal cortex, parahippocampus, fusiform, banks of
the superior temporal sulcus (BSTS), transverse temporal
lobe, temporal pole, and the inferior, middle and superior
temporal lobe; the isthmus cingulate, precuneus, supra-
marginal gyrus, and the inferior and superior parietal
lobe; the pars orbitalis, pars triangularis, pars opercularis,
lateral and medial orbitofrontal, pre- and paracentral,
rostral, caudal, middle and superior frontal lobe; and the
cuneus, lingual, pericalcarine, and lateral occipital lobe.
Full details of PET acquisition and analysis can be found
at http://adni.loni.usc.edu/methods/.
CSF samples were analysed for CSF Ab42 using the
AlzBio3 assay (Fujirebio, Ghent, Belgium) on the xMAP
Luminex platform and have been described previously
(Olsson et al., 2005; Shaw et al., 2009). CSF Ab
<192 ng/L defined CSF Abþ.
Statistical analysis
Continuous disease time, an alternative to discrete diag-
nostic categories, as described and estimated previously
(Donohue et al., 2014; Li et al., 2017, 2018) was used
to model the spread of regional uptake in Ab and tau
PET (not used in the estimation of disease time). Disease
time is a measure of disease severity, estimated from a
Bayesian latent time joint-mixed effects model (LTJMM).
Briefly, for subject i (i¼ 1, . . ., n), outcome k (k¼ 1, . . .,
p), at time t[ijk] (j¼ 1, . . ., qik) the model is of the form:
yijk ¼ x0t ijk½ bk þ ck t ijk½  þ dið Þ þ a0ik þ a1ikt ijk½  þ eijk;
where yijk are the observed outcome, x
0
t ijk½  are vectors of
predictors, bk are fixed effects, ck are the disease time
slopes, t ijk½  þ di are the shifted disease times, a are ran-
dom effects and e are multivariate Gaussian residuals.
Jointly modeled outcomes included cognitive data (the
13-item Alzheimer’s disease assessment scale, cognitive
subscale, the mini-mental state exam, the Functional
Activities Questionnaire, the Rey Auditory Visual
Learning Test, the CDR Sum of Boxes and the Preclinical
Alzheimer Cognitive Composite), CSF data (Ab, phos-
phorylated tau and total tau), MRI volumes (hippocam-
pus, entorhinal cortex, fusiform, middle temporal gyrus,
ventricles and whole-brain volume) and PET imaging of
global amyloid burden and glucose metabolism in the
brain. LTJMM provides estimates of disease severity
while accounting for the dependency between different
markers. Prior to modeling, outcomes are transformed to
quantiles, then transformed again to Z-scores via the in-
verse Gaussian cumulative distribution function. See Li
et al. (2018) for more detail.
The relationship between longitudinal uptake in PET
ROIs and disease time was examined using mixed-effects
models with random intercepts. Natural splines were
used to capture departures from linearity with respect to
disease time. Spline knots were placed at the median and
boundaries of disease time, with the number of knots
selected by Akaike information criterion. PET responses
were covaried for age, sex and mean Ab PET uptake in
the whole cerebellum for Ab ROIs and mean tau PET
uptake in the inferior cerebellar grey matter for tau
ROIs.
We used a positional variance diagram to depict the
temporal ordering of the ROIs. For a specific point on
the disease time axis, ROIs were ordered by PET uptake.
The positional variance diagram shows the proportion of
500 bootstrap samples in which a particular ROI appears
in a particular position in the central ordering. Positional
variance was assessed 15, 10 and 5 years before the esti-
mated time of AD dementia diagnosis.
To further inspect early development of Ab and tau
pathology, changes in mean uptake with small increases
in disease time (first derivatives of uptake curves) were
plotted to show how the regional slopes of accumulation
accelerate over disease time. Ab regions with high mean
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uptake early on the spectrum of disease time and contin-
ued increase with advances in disease time were evaluated
further in the validation sample. Baseline and longitudinal
change in a composite of regions with early uptake were
compared to a commonly used global composite (com-
prising regions throughout the frontal, parietal and tem-
poral lobes and cingulate gyrus; Landau et al., 2012) in
a sample of CSF Ab CU participants, and separately,
CSF Abþ CU participants. Baseline and accumulation
rate differences between early and global estimates were
tested using t-tests with bootstrap estimated standard
errors.
To estimate power for Ab PET end-points in hypothet-
ical primary and secondary prevention trials, mixed-
model estimates were used to calculate the power for
24-month clinical trials, assuming a range of sample sizes,
a 100% slowing of Ab accumulation, a 12-month visit
interval and a 30% dropout rate.
Associations between diagnosis and demographics were
assessed using Wilcoxon rank-sum test for continuous
variables and Fisher’s Exact test for categorical variables.
All analyses were done in R v3.5.1 (www.r-project.org).
Data availability
All data are publicly available at http://adni.loni.usc.edu/.
Results
Cohort characteristics
One-hundred and eighty-three CU (102Ab and
81Abþ), 61Abþ MCI (including 10 individuals who
progressed from CU to MCI during follow-up) and
35Abþ AD participants (including 28 MCI to AD pro-
gressors) were included in the analysis. Mean follow-up
time was 4.0 years (SD¼ 2.6). Seventy-seven participants
had one Ab PET scan, 25 had two scans, 77 had three
scans and 100 had four or more scans. Two-hundred
and nineteen participants had one tau PET scan, 52 had
two scans and 8 had three scans. Participants had a
mean age of 72 years (55–90 years), 145 (52%) were fe-
male, they had a mean of 16.5 years of education (12–
20) and 114 (42%) were APOE e4 carriers.
Demographics are summarized in Table 1.
Disease time
Disease time was estimated for each individual (estimated
previously in Li et al., 2018). Disease time was centred
on the average observed time of progression to an AD
dementia diagnosis, making the measure interpretable at
disease time ¼ 0. The average disease time was 10,
ranging from 18 to 6. The distribution of disease time
by diagnosis is shown in Fig. 1 and summarized in
Table 1. In 28 participants with an observed time of pro-
gression to AD, the correlation between estimated disease
time and progression to AD was 0.74 (P< 0.001).
Regional Ab and tau PET
Trajectories of all Ab and tau PET ROIs are plotted
against disease time in Fig. 2. Several patterns emerge, as
described in more detail below. Several Ab PET regions
follow a similar pattern of high initial elevation with re-
spect to disease time and continued increase as disease
time approaches the time of an AD diagnosis. A younger
sample would be required to characterize the earliest
Table 1 Demographics and baseline disease time
Characteristic CU pCU EMCI LMCI AD
(N5183) (N5 10) (N530) (N5 21) (N5 35) P-value
Age 71.5 (5.9) 77.0 (6.3) 69.9 (6.6) 70.5 (7.6) 74.0 (7.3) 0.01
Sex, female, n (%) 105 (57.4) 6 (60.0) 7 (23.3) 10 (47.6) 17 (48.6) 0.01
Education (years), n (%) 16.9 (2.4) 16.4 (2.8) 15.9 (2.9) 16.2 (2.6) 15.6 (2.6) 0.03
APOE e4þ, n (%) 59 (32.8) 5 (50.0) 20 (66.7) 13 (61.9) 17 (50.0) <0.01
Disease time (years), n (%) 11.5 (3.0) 8.4 (1.7) 9.3 (3.0) 4.4 (4.0) 3.4 (3.9) <0.01
Figure 1 Disease time distributions. Distributions of baseline
disease time are shown by diagnosis (pCU: CU to MCI progressors,
EMCI: early MCI, LMCI: late MCI , AD: AD dementia). Disease time
was re-centred so that time 0 corresponds to the mean time of
progression from MCI to dementia.
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changes in these regions. This pattern is most noticeable
in the posterior cingulate and precuneus (Fig. 2A and B).
High levels of uptake are also seen initially in the isth-
mus cingulate, inferior parietal and lateral orbitofrontal
cortex, but increased more modestly. The main tau PET
region to follow this pattern of a high initial level and a
steep increase was the inferior temporal lobe. The ento-
rhinal cortex also showed a steep increase in tau uptake,
as well as the fusiform, middle temporal lobe and the in-
ferior parietal lobe. The amygdala and the BSTS showed
high initial tau uptake levels, but increased modestly.
Spaghetti plots of uptake of several select ROIs are
shown in Fig. 3. To more closely examine how accumu-
lation is accelerating over the course of disease time, we
plotted the first derivatives of the uptake curves against
disease time in Fig. 4. These plots show the change in
uptake over small advances in disease time. The posterior
cingulate and isthmus cingulate show the highest initial
rates of increase of Ab uptake with respect to disease
time. However, the rate of isthmus cingulate increases
minimally over time. A similar pattern is seen in the cau-
dal anterior cingulate. Large rate increases are seen in the
other regions, especially in the precuneus, middle tem-
poral lobe and the lateral orbitofrontal cortex.
Initial tau uptake slopes are steepest in the amygdala,
BSTS and the inferior temporal lobe. However, the infer-
ior temporal lobe quickly accelerates, while both the
amygdala and BSTS begin to plateau. While the initial
slope is more gradual in the entorhinal cortex, fusiform
gyrus and middle temporal lobe, all start to accelerate,
similar to the inferior temporal lobe.
Order
A positional variance diagram, depicting the order of all
PET ROIs by uptake 10 years before an AD diagnosis
(disease time ¼ 10), is shown in Fig. 5. Ten years be-
fore an AD diagnosis, the Ab PET ROIs with the highest
mean uptake were the posterior cingulate, isthmus cingu-
late, caudal anterior cingulate and the precuneus. The tau
PET ROIs with the highest mean uptake were the amyg-
dala, inferior temporal lobe, BSTS and the fusiform
gyrus. The entorhinal cortex moved to the top half of the
order by 5 years before an AD diagnosis due to the slope
increase over the course of disease time; otherwise, the
ordering of the ROIs was stable at 15 and 5 years before
an AD diagnosis (Supplementary Figs 1 and 2).
Figure 2 Ab and tau PET ROIs. Mean uptake trajectories for Ab and tau PET ROIs are plotted against disease time along with 95% CI
depicted by the shaded regions. Ab ROIs are shown in A–D, with a separate plot for each lobe. Tau ROIs are shown in E–H.
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Early composite performance in the
validation sample
To evaluate the performance of the regions selected by
the LTJMM models, an outside validation sample consist-
ing of 111 CSF Ab and 77 CSF Abþ CU participants
was used. The average follow-up time of the validation
sample was 2.7 years (2.8 in the Ab group and 2.5 in
the Abþ group). Participants were 74 years old on
average, 51% female, had an average of 16 years of edu-
cation, and were 23% APOE e4þ.
Based on early uptake patterns, a volume-weighted
average of the posterior cingulate and the precuneus were
used to form the early Ab PET composite. In Ab CU
participants from the validation sample, there was signifi-
cantly more Ab uptake at baseline in the early composite
compared to the global composite (1.25 versus 1.19,
SE¼ 0.005, P< 0.001). In Ab CU, Ab uptake in the
Figure 3 Select Ab and tau PET ROIs. Mean uptake trajectories for key Ab and tau PET ROIs are plotted against disease time along with
observed subject-level data, colour coded by diagnosis. 95% CI are depicted by the shaded regions.
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early composite accumulated at a rate of 0.006/year
[95% confidence interval (CI): 0.003–0.09, P< 0.001),
compared to 0.003/year in the global composite (95%
CI: 0.0001 to 0.006, P¼ 0.06). The accumulation rate
in the early composite was more than double the rate
(120% increase, P< 0.001) of the global composite, in
the Ab CU participants.
In Abþ CU, there was significantly more uptake in the
early composite at baseline compared to the global com-
posite (1.65 versus 1.50, SE¼ 0.01, P< 0.001). The accu-
mulation rate in the early composite was 0.013/year
(95% CI: 0.003, 0.023, P¼ 0.01) and was not signifi-
cantly different from the accumulation rate in the global
composite, 0.012/year (95% CI: 0.003, 0.020, P¼ 0.01).
Plots of baseline and change estimates are shown in
Fig. 6A–D.
Power calculations for primary and
secondary prevention trials
To reach 80% power in a 24-month primary prevention
trial of Ab CU participants to detect a slowing of Ab
deposition, 233 subjects/arm would be required, using the
early composite. Using the global composite with 233
subjects/arm would result in 50% power; for 80%
power, 481 subjects/arm would be required.
To reach 80% power in a 24-month secondary preven-
tion trial of Abþ CU participants to detect a slowing of
Ab deposition, 110 subjects/arm would be required, using
the early composite. Similarly, to reach 80% power using
the global composite, 106 subjects/arm would be
required. Plots of power by the required sample size for
hypothetical treatment trials are shown in Fig. 6E and F.
Discussion and conclusions
As the details of early biomarker changes in AD emerge,
early detection and diagnosis of disease may improve by
considering disease progression on its natural continuum
without relying on discrete stages with artificial bounda-
ries. By integrating biomarker and clinical data to deter-
mine each individual’s location on a pathological
timeline, the earliest changes in disease progression can
be accurately detected and examined. In Fig. 1, the peaks
of the disease time distributions align with clinical stages,
although the overlap demonstrates the wide variation
that is ignored when individuals are grouped discretely.
As seen in Fig. 2, Ab PET uptake levels in the posterior
cingulate and precuneus start high and immediately in-
crease with small advances in disease time, followed by
multiple frontal lobe regions, especially the lateral orbito-
frontal cortex, and then several parietal ROIs, with little
crossing of trajectories. These regions align with multiple
recent independent reports of early Ab accumulation con-
sistently found in the posterior cingulate, precuneus and
superior frontal lobe, as well as the orbitofrontal and in-
ferior/middle temporal lobes (Villemagne et al., 2011;
Vlassenko et al., 2011; Mormino et al., 2012; Villain
Figure 4 PETuptake change. First derivatives of the PETuptake curves are plotted against disease time for several key ROIs. Changes in the
mean uptake with small increases in disease time show how the slopes of accumulation accelerate over disease time. Ab ROIs are shown on the
left and tau PET ROIs on the right.
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et al., 2012; Sojkova et al., 2013; Cho et al., 2016;
Palmqvist et al., 2017, Mattsson et al., 2019c).
Similarly, early elevation and increases in tau PET up-
take were found in the inferior temporal lobe, amygdala,
BSTS and fusiform gyrus, and also the entorhinal cortex,
inferior parietal lobe, middle temporal lobe and the pre-
cuneus. Uptake in multiple medial temporal lobe ROIs
starts slightly higher and accelerates early, followed by
lateral temporal and parietal lobe ROIs (Figs 2 and 3).
These regions, demonstrating early elevated tau PET up-
take, also coincide with several reports consistently find-
ing elevated uptake primarily in the inferior temporal
lobe, fusiform and entorhinal cortex, as well as the
amygdala, parahippocampus and middle temporal lobe
(Cho et al., 2016; Johnson et al., 2016; Scho¨ll et al.,
2016; Vemuri et al., 2017; Schultz et al., 2018, Mattsson
et al., 2019b).
The order of both Ab and tau PET ROIs remains
mostly stable at different cross-sections of the disease
time scale, with the exception that uptake in the entorhi-
nal cortex accelerates quickly across disease time and
moves up in the order. Several ROIs show initially ele-
vated uptake but increase modestly with advancing dis-
ease severity. This is the case for several anterior
cingulate regions in terms of Ab uptake, including the
caudal and rostral anterior cingulate. Similarly, several
frontal regions, such as the lateral orbitofrontal cortex
and the pars orbitalis/triangularis, show elevated tau up-
take early, but do not increase at the same rate as either
temporal or parietal regions, potentially due in part to
the off-target binding.
The observed early pattern of uptake points to the pos-
terior cingulate and precuneus as candidate ROIs for a
targeted Ab composite. In the validation sample, the rate
of Ab uptake in the early composite was more than twice
the rate observed in the global composite, in the CSF
Ab participants. By streamlining the commonly used
global composite to include only the posterior cingulate
and precuneus, the doubled rate of Ab uptake resulted in
a 60% increase in the estimated power to detect a hypo-
thetical treatment effect in a primary prevention clinical
trial. In the CSF Abþ participants, there was no
Figure 5 Positional variance diagram. The ordering of all ROIs with respect to disease time (at disease time ¼ 10) is shown on the
diagonal of the diagram. The positional variance diagram shows the proportion of 500 bootstrap samples in which a particular ROI appears in a
particular position in the central ordering, ranging from 0 (white or no shading) to 1 (blue shading). ROIs are ordered by their most frequently
estimated position with uncertainty captured by the transparency of the shading. Earliest accumulators are show on the top left and latest on the
bottom right. Solid blue indicates increased certainty with regard to position in the order while more transparency indicates less certainty, as
estimated by the bootstrap.
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difference in the rate of Ab PET uptake, suggesting that
the excluded regions from the early composite are now
accumulating at a similar rate observed in the early com-
posite. Such an early composite could be used to re-
examine the thresholds for Ab-related study inclusion, es-
pecially as the field shifts to focus on secondary and pri-
mary prevention. Clinical trials of anti-Ab treatments
may benefit from the use of an early Ab composite when
estimating drug effects on Ab changes in populations
with minimal Ab deposition and limited expected short-
term accumulation.
Similarly, an early tau composite comprising the infer-
ior temporal lobe, entorhinal cortex, amygdala, BSTS,
middle temporal lobe, inferior parietal lobe and the fusi-
form gyrus could aid in detecting the earliest tau changes.
Additional longitudinal tau PET data will be required to
provide further evidence for such a composite and
whether it can be optimized to correlate with early Ab
changes, neurodegeneration and the onset of cognitive
symptoms.
This study is limited by its follow-up on participants
younger than 65 years of age. Precise estimates of early
change will require additional longitudinal follow-up
focused on a younger cohort. Incorporation of emerging
biomarkers such as blood-based measures of amyloid dys-
regulation (Nakamura et al., 2018; Schindler et al., 2019)
Figure 6 Early and global composite estimates and clinical trial power. Boxplots of estimates of Ab PETuptake in early and global
composites in the validation cohort. A and B show baseline estimates for CSF Ab and CSF Abþ, respectively. C and D show rate estimates
(Ab PETuptake change/year) for CSF Ab and CSF Abþ participants. Plots of clinical trial power by sample size for primary prevention (Ab,
E) and secondary prevention (Abþ, F), for early and global composites, separately.
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and neurodegeneration (Mattsson et al., 2019a) into this
effort will further clarify the course of AD.
Ordering participants on a continuous disease time
scale, jointly estimated from biomarker, imaging and cog-
nitive data, facilitates the inspection of the earliest signs
of Ab and tau pathology in the healthiest participants,
informing conceptualization of the pathophysiologic proc-
esses underlying the disease. Identifying the sequence of
brain regions where deposition is initiated will aid in the
design of Ab and tau composites optimized to detect and
monitor disease progression facilitating the design of feas-
ible prevention studies in AD.
Supplementary material
Supplementary material is available at Brain
Communications online.
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